SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure
Synthetic Biologics, Inc. (the Company) will be making several
investor presentations over the next couple of weeks, including a
presentation at the Biotech Showcase 2017 Conference on January
9, 2017, in San Francisco, California. In connection with the
presentations, the Company intends to discuss the slide
presentation furnished as Exhibit 99.1 hereto, which is
incorporated herein by reference.
The slide presentation attached as Exhibit 99.1 to this Report
includes safe harbor language to the Private Securities
Litigation Reform Act of 1995, as amended, indicating that
certain statements contained in the slide presentation or in the
press release are forward-looking rather than historical.
The information included in this Item 7.01 and in Exhibit 99.1
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that Section or
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. The
Company undertakes no duty or obligation to update or revise
information included in this Report or any of the Exhibits.
Item 9.01. Financial Statements and Exhibits
The following exhibit is being filed as part of this Report.
Presentation materials to be provided at Synthetic Biologics,
About SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN)
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU). SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Recent Trading Information
SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) closed its last trading session up +0.037 at 0.930 with 594,327 shares trading hands.